Beth C. Seidenberg's most recent trade in Sagimet Biosciences Inc - Ordinary Shares - Class A was a trade of 32,250 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 6, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sagimet Biosciences Inc - ... | Beth C. Seidenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2025 | 32,250 | 32,250 | - | - | Stock Option (Right to Buy) | |
| Sagimet Biosciences Inc - ... | Beth C. Seidenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2025 | 28,522 | 28,522 | - | - | Stock Option (Right to Buy) | |
| Kyverna Therapeutics Inc. | Beth C. Seidenberg | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 65,351 | 65,351 | - | - | Stock Option (right to buy) | |
| Kyverna Therapeutics Inc. | Beth C. Seidenberg | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 16,634 | 16,634 | - | 0 | Common Stock | |
| Vera Therapeutics Inc - Or... | Beth C. Seidenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2025 | 14,000 | 14,000 | - | - | Stock Option (right to buy) | |
| Vera Therapeutics Inc - Or... | Beth C. Seidenberg | Director | Sale of securities on an exchange or to another person at price $ 48.01 per share. | 28 Oct 2024 | 14,798 | 131,755 | - | 48.0 | 710,486 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Beth C. Seidenberg | Director | Sale of securities on an exchange or to another person at price $ 49.54 per share. | 28 Oct 2024 | 202 | 131,553 | - | 49.5 | 10,007 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Beth C. Seidenberg | Director | Sale of securities on an exchange or to another person at price $ 42.31 per share. | 18 Sep 2024 | 13,823 | 146,553 | - | 42.3 | 584,793 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Beth C. Seidenberg | Director | Sale of securities on an exchange or to another person at price $ 42.00 per share. | 18 Sep 2024 | 1,476 | 4,012 | - | 42 | 61,992 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Beth C. Seidenberg | Director | Sale of securities on an exchange or to another person at price $ 42.01 per share. | 18 Sep 2024 | 1,177 | 160,376 | - | 42.0 | 49,448 | Class A Common Stock |
| Acelyrin Inc | Beth C. Seidenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 92,158 | 92,158 | - | - | Director Stock Option (right to buy) | |
| Sagimet Biosciences Inc - ... | Beth C. Seidenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 51,459 | 51,459 | - | - | Stock Option (Right to Buy) | |
| Progyny Inc | Beth C. Seidenberg | Director | 23 May 2024 | 26,926 | 26,926 | - | - | Stock Option (Right to Buy) | ||
| Progyny Inc | Beth C. Seidenberg | Director | 23 May 2024 | 7,206 | 43,416 (0%) | 0% | 0 | Common Stock | ||
| Vera Therapeutics Inc - Or... | Beth C. Seidenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2024 | 14,000 | 14,000 | - | - | Stock Option (right to buy) | |
| Kyverna Therapeutics Inc. | Beth C. Seidenberg | Director, Ten Percent Owner | 12 Feb 2024 | 8,830,901 | 0 | - | - | Series A-2 Redeemable Convertible Preferred Stock | ||
| Kyverna Therapeutics Inc. | Beth C. Seidenberg | Director, Ten Percent Owner | 12 Feb 2024 | 4,401,771 | 0 | - | - | Series A-1 Redeemable Convertible Preferred Stock | ||
| Kyverna Therapeutics Inc. | Beth C. Seidenberg | Director, Ten Percent Owner | 12 Feb 2024 | 4,006,624 | 0 | - | - | Series B Redeemable Convertible Preferred Stock | ||
| Kyverna Therapeutics Inc. | Beth C. Seidenberg | Director, Ten Percent Owner | 12 Feb 2024 | 3,787,940 | 3,787,940 | - | - | Common Stock | ||
| Kyverna Therapeutics Inc. | Beth C. Seidenberg | Director, Ten Percent Owner | 12 Feb 2024 | 3,349,538 | 0 | - | - | Series B Redeemable Convertible Preferred Stock | ||
| Kyverna Therapeutics Inc. | Beth C. Seidenberg | Director, Ten Percent Owner | 12 Feb 2024 | 735,984 | 735,984 | - | - | Common Stock | ||
| Sagimet Biosciences Inc - ... | Beth C. Seidenberg | Director | 18 Jul 2023 | 103,127,234 | 0 | - | - | Series E Preferred Stock | ||
| Sagimet Biosciences Inc - ... | Beth C. Seidenberg | Director | 18 Jul 2023 | 20,430,107 | 0 | - | - | Series F Preferred Stock | ||
| Sagimet Biosciences Inc - ... | Beth C. Seidenberg | Director | 18 Jul 2023 | 8,596,590 | 0 | - | - | Series B-1 Preferred Stock | ||
| Sagimet Biosciences Inc - ... | Beth C. Seidenberg | Director | 18 Jul 2023 | 8,596,589 | 0 | - | - | Series C Preferred Stock | ||
| Sagimet Biosciences Inc - ... | Beth C. Seidenberg | Director | 18 Jul 2023 | 6,737,254 | 0 | - | - | Series E Preferred Stock | ||
| Sagimet Biosciences Inc - ... | Beth C. Seidenberg | Director | 18 Jul 2023 | 6,103,580 | 0 | - | - | Series D Preferred Stock | ||
| Sagimet Biosciences Inc - ... | Beth C. Seidenberg | Director | 18 Jul 2023 | 1,860,712 | 1,899,475 | - | - | Series A Common Stock | ||
| Sagimet Biosciences Inc - ... | Beth C. Seidenberg | Director | 18 Jul 2023 | 539,006 | 0 | - | - | Series A Preferred Stock | ||
| Sagimet Biosciences Inc - ... | Beth C. Seidenberg | Director | 18 Jul 2023 | 493,370 | 0 | - | - | Series B Preferred Stock | ||
| Sagimet Biosciences Inc - ... | Beth C. Seidenberg | Director | 18 Jul 2023 | 84,768 | 84,768 | - | - | Series A Common Stock | ||
| Sagimet Biosciences Inc - ... | Beth C. Seidenberg | Director | Purchase of securities on an exchange or from another person at price $ 16.00 per share. | 18 Jul 2023 | 46,875 | 46,875 | - | 16 | 750,000 | Series A Common Stock |
| Sagimet Biosciences Inc - ... | Beth C. Seidenberg | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 38,763 | 0 | - | - | Common Stock | |
| Sagimet Biosciences Inc - ... | Beth C. Seidenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 38,763 | 38,763 | - | - | Series A Common Stock | |
| Sagimet Biosciences Inc - ... | Beth C. Seidenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 23,216 | 23,216 | - | - | Stock Option (Right to Buy) | |
| Sagimet Biosciences Inc - ... | Beth C. Seidenberg | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 23,216 | 0 | - | - | Stock Option (Right to Buy) | |
| Progyny Inc | Beth C. Seidenberg | Director | 23 Jun 2023 | 17,162 | 0 (0%) | 0% | 0 | Common Stock | ||
| Progyny Inc | Beth C. Seidenberg | Director | 23 Jun 2023 | 10,284 | 36,210 (0%) | 0% | 0 | Common Stock | ||
| Progyny Inc | Beth C. Seidenberg | Director | 09 Jun 2023 | 1,398,900 | 5,074,615 (6%) | 1% | 0 | Common Stock | ||
| Progyny Inc | Beth C. Seidenberg | Director | 09 Jun 2023 | 264,608 | 264,608 (0%) | 0% | 0 | Common Stock | ||
| Progyny Inc | Beth C. Seidenberg | Director | 09 Jun 2023 | 247,446 | 17,162 (0%) | 0% | 0 | Common Stock | ||
| Progyny Inc | Beth C. Seidenberg | Director | 09 Jun 2023 | 6,656 | 25,926 (0%) | 0% | 0 | Common Stock | ||
| Progyny Inc | Beth C. Seidenberg | Director | 24 May 2023 | 19,709 | 19,709 | - | - | Stock Option (Right to Buy) | ||
| Progyny Inc | Beth C. Seidenberg | Director | 24 May 2023 | 5,116 | 19,270 (0%) | 0% | 0 | Common Stock | ||
| Progyny Inc | Beth C. Seidenberg | Director | 24 May 2023 | 3,261 | 3,261 | - | - | Stock Option (Right to Buy) | ||
| Vera Therapeutics Inc - Or... | Beth C. Seidenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2023 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Acelyrin Inc | Beth C. Seidenberg | Director, Ten Percent Owner | 09 May 2023 | 8,540,729 | 8,540,729 | - | - | Common Stock | ||
| Acelyrin Inc | Beth C. Seidenberg | Director, Ten Percent Owner | 09 May 2023 | 4,056,795 | 0 | - | - | Series A Redeemable Convertible Preferred Stock | ||
| Acelyrin Inc | Beth C. Seidenberg | Director, Ten Percent Owner | 09 May 2023 | 2,445,786 | 0 | - | - | Series B Redeemable Convertible Preferred Stock | ||
| Acelyrin Inc | Beth C. Seidenberg | Director, Ten Percent Owner | 09 May 2023 | 2,038,148 | 0 | - | - | Series C Redeemable Convertible Preferred Stock | ||
| Acelyrin Inc | Beth C. Seidenberg | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 09 May 2023 | 1,250,000 | 9,790,729 | - | 18 | 22,500,000 | Common Stock |
| Acelyrin Inc | Beth C. Seidenberg | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 09 May 2023 | 60,000 | 60,000 | - | 18 | 1,080,000 | Common Stock |
| Acelyrin Inc | Beth C. Seidenberg | Director, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 09 May 2023 | 23,243 | 23,243 | - | - | Director Stock Option (right to buy) | |
| Acelyrin Inc | Beth C. Seidenberg | Director, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 09 May 2023 | 23,243 | 0 | - | - | Director Stock Option (right to buy) | |
| Acelyrin Inc | Beth C. Seidenberg | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2023 | 23,243 | 23,243 | - | - | Director Stock Option (right to buy) | |
| Vera Therapeutics Inc - Or... | Beth C. Seidenberg | Director | Purchase of securities on an exchange or from another person at price $ 7.24 per share. | 30 Mar 2023 | 2,300 | 1,949,295 | - | 7.2 | 16,651 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Beth C. Seidenberg | Director | Purchase of securities on an exchange or from another person at price $ 7.24 per share. | 28 Mar 2023 | 23,908 | 1,946,995 | - | 7.2 | 173,192 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Beth C. Seidenberg | Director | Purchase of securities on an exchange or from another person at price $ 7.24 per share. | 24 Mar 2023 | 1,833 | 1,921,454 | - | 7.2 | 13,272 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Beth C. Seidenberg | Director | Purchase of securities on an exchange or from another person at price $ 7.24 per share. | 24 Mar 2023 | 1,633 | 1,923,087 | - | 7.2 | 11,830 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Beth C. Seidenberg | Director | Purchase of securities on an exchange or from another person at price $ 7.12 per share. | 17 Mar 2023 | 74,045 | 1,904,369 | - | 7.1 | 526,882 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Beth C. Seidenberg | Director | Purchase of securities on an exchange or from another person at price $ 7.21 per share. | 17 Mar 2023 | 15,252 | 1,919,621 | - | 7.2 | 110,033 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Beth C. Seidenberg | Director | Purchase of securities on an exchange or from another person at price $ 7.09 per share. | 15 Mar 2023 | 60,097 | 1,830,324 | - | 7.1 | 426,268 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Beth C. Seidenberg | Director | Purchase of securities on an exchange or from another person at price $ 7.12 per share. | 15 Mar 2023 | 32,844 | 1,770,227 | - | 7.1 | 234,010 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Beth C. Seidenberg | Director | Purchase of securities on an exchange or from another person at price $ 7.16 per share. | 10 Mar 2023 | 48,003 | 1,737,383 | - | 7.2 | 343,485 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Beth C. Seidenberg | Director | Purchase of securities on an exchange or from another person at price $ 7.24 per share. | 03 Mar 2023 | 1,000 | 1,689,380 | - | 7.2 | 7,245 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Beth C. Seidenberg | Director | Purchase of securities on an exchange or from another person at price $ 7.24 per share. | 01 Mar 2023 | 23,378 | 1,688,380 | - | 7.2 | 169,322 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Beth C. Seidenberg | Director | Purchase of securities on an exchange or from another person at price $ 7.25 per share. | 01 Mar 2023 | 100 | 1,665,002 | - | 7.3 | 725 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Beth C. Seidenberg | Director | Purchase of securities on an exchange or from another person at price $ 7.24 per share. | 23 Feb 2023 | 200 | 1,664,902 | - | 7.2 | 1,447 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Beth C. Seidenberg | Director | Purchase of securities on an exchange or from another person at price $ 7.20 per share. | 13 Feb 2023 | 10,072 | 1,664,702 | - | 7.2 | 72,490 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Beth C. Seidenberg | Director | Purchase of securities on an exchange or from another person at price $ 7.25 per share. | 09 Feb 2023 | 400 | 1,654,630 | - | 7.3 | 2,900 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Beth C. Seidenberg | Director | Purchase of securities on an exchange or from another person at price $ 7.03 per share. | 03 Feb 2023 | 131,602 | 1,520,917 | - | 7.0 | 925,162 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Beth C. Seidenberg | Director | Purchase of securities on an exchange or from another person at price $ 7.08 per share. | 03 Feb 2023 | 87,956 | 1,608,873 | - | 7.1 | 622,728 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Beth C. Seidenberg | Director | Purchase of securities on an exchange or from another person at price $ 7.24 per share. | 03 Feb 2023 | 46,163 | 1,389,315 | - | 7.2 | 334,220 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Beth C. Seidenberg | Director | Purchase of securities on an exchange or from another person at price $ 7.22 per share. | 03 Feb 2023 | 45,357 | 1,654,230 | - | 7.2 | 327,478 | Class A Common Stock |
| Progyny Inc | Beth C. Seidenberg | Director | 24 Oct 2022 | 22,999 | 10,094 (0%) | 0% | 0 | Common Stock | ||
| Progyny Inc | Beth C. Seidenberg | Director | 24 Oct 2022 | 22,999 | 227,906 (0%) | 0% | 0 | Common Stock | ||
| Progyny Inc | Beth C. Seidenberg | Director | 24 Oct 2022 | 16,820 | 16,820 | - | - | Stock Option (Right to Buy) | ||
| Progyny Inc | Beth C. Seidenberg | Director | 24 Oct 2022 | 4,060 | 14,154 (0%) | 0% | 0 | Common Stock | ||
| Progyny Inc | Beth C. Seidenberg | Director | 24 Oct 2022 | 1,898 | 1,898 | - | - | Stock Option (Right to Buy) | ||
| Atara Biotherapeutics Inc | Beth C. Seidenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 31,500 | 31,500 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Atara Biotherapeutics Inc | Beth C. Seidenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 20,500 | 58,689 (0%) | 0% | 0 | Common Stock | |
| Vera Therapeutics Inc - Or... | Beth C. Seidenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2022 | 9,925 | 9,925 | - | - | Stock Option (right to buy) | |
| Progyny Inc | Beth C. Seidenberg | Director | 22 Dec 2021 | 19,265 | 0 (0%) | 0% | 0 | Common Stock | ||
| Progyny Inc | Beth C. Seidenberg | Director | 22 Dec 2021 | 15,250 | 33,093 (0%) | 0% | 0 | Common Stock | ||
| Progyny Inc | Beth C. Seidenberg | Director | 17 Nov 2021 | 932,600 | 6,473,515 (7%) | 1% | 0 | Common Stock | ||
| Progyny Inc | Beth C. Seidenberg | Director | 17 Nov 2021 | 306,560 | 306,560 (0%) | 0% | 0 | Common Stock | ||
| Progyny Inc | Beth C. Seidenberg | Director | 17 Nov 2021 | 287,295 | 19,265 (0%) | 0% | 0 | Common Stock | ||
| Progyny Inc | Beth C. Seidenberg | Director | 17 Nov 2021 | 7,749 | 17,843 (0%) | 0% | 0 | Common Stock | ||
| Progyny Inc | Beth C. Seidenberg | Director | 16 Sep 2021 | 32,802 | 7,000 (0%) | 0% | 0 | Common Stock | ||
| Progyny Inc | Beth C. Seidenberg | Director | 16 Sep 2021 | 17,003 | 17,003 | - | - | Stock Option (right to buy) | ||
| Progyny Inc | Beth C. Seidenberg | Director | 16 Sep 2021 | 3,094 | 10,094 (0%) | 0% | 0 | Common Stock | ||
| Progyny Inc | Beth C. Seidenberg | Director | 16 Sep 2021 | 2,813 | 2,813 | - | - | Stock Option (right to buy) | ||
| Progyny Inc | Beth C. Seidenberg | Director | 19 Jul 2021 | 29,494 | 0 (0%) | 0% | 0 | Common Stock | ||
| Progyny Inc | Beth C. Seidenberg | Director | 19 Jul 2021 | 20,994 | 39,802 (0%) | 0% | 0 | Common Stock | ||
| Progyny Inc | Beth C. Seidenberg | Director | 21 Jun 2021 | 1,398,900 | 7,406,115 (8%) | 1% | 0 | Common Stock | ||
| Progyny Inc | Beth C. Seidenberg | Director | 21 Jun 2021 | 467,415 | 467,415 (0%) | 0% | 0 | Common Stock | ||
| Progyny Inc | Beth C. Seidenberg | Director | 21 Jun 2021 | 437,921 | 29,494 (0%) | 0% | 0 | Common Stock | ||
| Progyny Inc | Beth C. Seidenberg | Director | 21 Jun 2021 | 84,964 | 172,105 (0%) | 0% | 0 | Common Stock | ||
| Progyny Inc | Beth C. Seidenberg | Director | 21 Jun 2021 | 84,964 | 7,000 (0%) | 0% | 0 | Common Stock | ||
| Progyny Inc | Beth C. Seidenberg | Director | 21 Jun 2021 | 11,808 | 18,808 (0%) | 0% | 0 | Common Stock | ||
| Atara Biotherapeutics Inc | Beth C. Seidenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 17,500 | 17,500 | - | - | Non-Qualified Stock Option (Right to Buy) |